Sign in
Taking peoplePhase 3

VAsopressin and STeroids in Addition to Adrenaline in Cardiac Arrest - a Randomized Clinical Trial

Key facts

Who runs it
Tiohundra AB
Where
Sweden4 sites in 1 countryChoose a country to see its sites
Status
Recruiting
Phase
Phase 3
People taking part
784 people, planned
Started
12 Oct 2026
Expected to end
30 Jun 2029
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Vasopressin; Methylprednisolone; Hydrocortisone
Record updated
12 November 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 5 criteriaShow less

Who can take part

  • Witnessed inhospital cardiac arrest, who meet the criteria for adrenaline administration according to current ERC guidelines
  • Men > 18 years and women > 50 years

Who cannot take part

  • Peroperative cardiac arrest
  • Out of hospital cardiac arrest, including rearrest at the emergency department or the intensive care unit
  • Patients with a do not resuscitate (DNR) decision

This trial is currently available in Sweden.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is an investigator initiated randomized, placebo controlled, open label, superiority, multi-centre clinical trial. The estimated study project period runs over 3-4 years, after now completed pilot phase. Based on preliminary assumptions, to confirm or reject an increase in survival from 16% to 24%, about 784 patients will be randomized in the study. In hospital cardiac arrest patients meeting criteria(s) for adrenaline administration according to current ERC guidelines, men > 18 years and women > 50, are eligible for randomization in the study.

Read full original descriptionShow less

Patients with do not resuscitate (DNR) decision will be excluded. Patients will be randomized to, in addition to adrenaline, either treatment with vasopressin and steroids (intervention) or standard care (control) Primary outcome is survival at 30 days.

The 2 groups in the trial

  • InterventionExisting treatment, for comparison

    Adrenaline, vasopressin and steroids arm (intervention) 1. At randomization 1 ml of vasopressin 20 IU/ml will be administered as soon as possible after adrenaline during the five first cycles of drug administration during CPR. 1 ml metylprednisolone sodium succinate 40 mg/ml will be administered only during the first cycle of drug administration during CPR 2. In the ICU Hydrocortisone 3 mg/ml At 4 hours post ROSC, and then once daily, surviving patients will receive an infusion of 100 ml (300 mg hydrocortisone/ d) for ≤ 5 days.

    Treatment: Vasopressin; Methylprednisolone; Hydrocortisone

  • ControlNo study treatment, for comparison

    Standard care in cardiac arrest

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Publications
Record updated
12 November 2026